China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence

China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence

CARTTherapy

#ssCART19 #CAR_T #CART #ALL #ICANS #CNSL #CARTTherapy

CAR-T therapy has reached another breakthrough with the introduction of ssCART-19, a new treatment that leverages IL-6 gene silencing technology to significantly reduce side effects, particularly when treating relapsed/refractory acute lymphoblastic leukemia (r/r ALL). Unlike traditional CAR-T therapies, ssCART-19 drastically lowers the risks of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

In the latest clinical trials, ssCART-19 demonstrated outstanding safety, with no patients experiencing ICANS, marking a milestone in CAR-T therapy safety. Among the 17 patients treated, 58.8% showed a significant increase in cell counts, and no cases of Grade 4 or higher CRS were reported. Additionally, ssCART-19 achieved an overall response rate (ORR) of 87.5% within three months, with nearly 63% of patients reaching complete remission.

The latest research also highlights that ssCART-19 outperforms traditional CAR-T products (cCART-19) in both safety and efficacy. Compared to conventional therapies, ssCART-19 significantly reduced the incidence of severe CRS, neutropenia, and ICANS, achieving an ORR of 91.5%. With these impressive results, ssCART-19 is expected to become a groundbreaking option for treating r/r ALL, offering new hope, especially for patients with central nervous system leukemia (CNSL).

Developed by a Chinese biopharmaceutical company, ssCART-19 has gained widespread recognition on the international stage, receiving Orphan Drug designation from the U.S. FDA and being listed as a breakthrough therapy in China. ssCART-19 offers a new treatment option for patients previously excluded from CAR-T therapy, greatly enhancing their chances of survival.

Stay tuned for more updates on how ssCART-19 is transforming cancer immunotherapy.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com